This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Y. Antero Kesäniemi, MD; Scott M. Grundy, MD, PhD

JAMA. 1984;251(17):2241-2246.

Abstract
Mechanisms for the hypolipidemic action of gemfibrozil were examined in seven patients with hypertriglyceridemia. In addition, seven hyperlipidemic patients were studied with and without clofibrate treatment to compare the mechanisms by which these two drugs lower plasma triglyceride levels. All patients were studied on a metabolic ward. The first month was a control period, followed by one month of either gemfibrozil or clofibrate therapy. During treatment with gemfibrozil, plasma total triglyceride levels decreased by an average of 51%, and triglyceride levels in very low—density lipoproteins (VLDLs) fell by 57%. Transport rates of VLDL triglyceride were determined by multicompartmental analysis following injection of tritiated glycerol as a precursor. Gemfibrozil decreased transport (production) of VLDL triglyceride by an average of 28% and increased the fractional catabolic rate (FCR) of VLDL triglyceride by 92%. Clofibrate reduced plasma total triglyceride values on an average of 32% and VLDL triglyceride values by 38%. In contrast to gemfibrozil, clofibrate did not change transport rates of VLDL triglyceride but increased the fractional catabolic rate of VLDL triglyceride by 35%. Gemfibrozil thus decreased production of VLDL triglyceride and enhanced its clearance, while clofibrate only increased clearance of VLDL triglyceride. On the average, plasma cholesterol levels did not fall during gemfibrozil treatment, but levels of cholesterol in high-density lipoproteins and in low-density lipoproteins increased by 31% and 11%, respectively. The drug produced a 30% increase in fecal excretion of neutral steroids and a 37% decrease in fecal excretion of bile acids. Outputs of total neutral steroids and net cholesterol balance thus remained unchanged.

(JAMA 1984;251:2241-2246)

Author Affiliations
From the Veterans Administration Medical Center and University of California, San Diego.

Footnotes
Reprint requests to Center of Human Nutrition (G4-100), University of Texas Health Science Center, 5323 Harry Hines Blvd, Dallas, TX 75235 (Dr Grundy).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Peroxisome proliferator-activated receptor {alpha} polymorphisms and postprandial lipemia in healthy men
Tanaka et al.
J. Lipid Res. 2007;48:1402-1408.
ABSTRACT | FULL TEXT  

PPAR{alpha} activation increases triglyceride mass and adipose differentiation-related protein in hepatocytes
Edvardsson et al.
J. Lipid Res. 2006;47:329-340.
ABSTRACT | FULL TEXT  

Differential regulation of cytosolic and peroxisomal bile acid amidation by PPAR{alpha} activation favors the formation of unconjugated bile acids
Solaas et al.
J. Lipid Res. 2004;45:1051-1060.
ABSTRACT | FULL TEXT  

Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz et al.
J. Lipid Res. 2004;45:174-185.
ABSTRACT | FULL TEXT  

PPAR{alpha} deficiency increases secretion and serum levels of apolipoprotein B-containing lipoproteins
Linden et al.
J. Lipid Res. 2001;42:1831-1840.
ABSTRACT | FULL TEXT  

Fibrates Suppress Bile Acid Synthesis via Peroxisome Proliferator-Activated Receptor-{alpha}-Mediated Downregulation of Cholesterol 7{alpha}-Hydroxylase and Sterol 27-Hydroxylase Expression
Post et al.
Arterioscler. Thromb. Vasc. Bio. 2001;21:1840-1845.
ABSTRACT | FULL TEXT  

The effects of gemfibrozil upon the metabolism of chylomicron-like emulsions in patients with endogenous hypertriglyceridemia
Santos et al.
Cardiovasc Res 2001;49:456-465.
ABSTRACT | FULL TEXT  

Long-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined Hyperlipidemia
Napoli et al.
J CARDIOVASC PHARMACOL THER 1997;2:17-26.
ABSTRACT  

Effects of Different Phenotypes of Hyperlipoproteinemia and of Treatment With Fibric Acid Derivatives on the Rates of Cholesterol 7{alpha}-Hydroxylation in Humans
Bertolotti et al.
Arterioscler. Thromb. Vasc. Bio. 1995;15:1064-1069.
ABSTRACT | FULL TEXT  

Lipoprotein Responses to Treatment With Lovastatin, Gemfibrozil, and Nicotinic Acid in Normolipidemic Patients With Hypoalphalipoproteinemia
Vega and Grundy
Arch Intern Med 1994;154:73-82.
ABSTRACT  

Pravastatin vs Gemfibrozil in the Treatment of Primary Hypercholesterolemia: The Italian Multicenter Pravastatin Study I
Crepaldi et al.
Arch Intern Med 1991;151:146-152.
ABSTRACT  

Cholesterol and Coronary Heart Disease: Future Directions
Grundy
JAMA 1990;264:3053-3059.
ABSTRACT  

The Hypolipidemic Effects of Gemfibrozil in Type V Hyperlipidemia: A Double-blind, Crossover Study
Leaf et al.
JAMA 1989;262:3154-3160.
ABSTRACT  

Reducing Hypertriglyceridemia in Elderly Patients with Cerebrovascular Disease Stabilizes or Improves Cognition and Cerebral Perfusion
Rogers et al.
ANGIOLOGY 1989;40:260-269.
ABSTRACT  

Lipid Alterations and Decline in the Incidence of Coronary Heart Disease in the Helsinki Heart Study
Manninen et al.
JAMA 1988;260:641-651.
ABSTRACT  

Combination Drug Therapy for Familial Combined Hyperlipidemia
East et al.
ANN INTERN MED 1988;109:25-32.
ABSTRACT  

Gemfibrozil Therapy in Primary Hypertriglyceridemia Associated With Coronary Heart Disease: Effects on Metabolism of Low-Density Lipoproteins
Vega and Grundy
JAMA 1985;253:2398-2403.
ABSTRACT  

The Peroxisome Proliferator-activated Receptor alpha (PPARalpha ) Regulates Bile Acid Biosynthesis
Hunt et al.
J. Biol. Chem. 2000;275:28947-28953.
ABSTRACT | FULL TEXT